Conflict of interest: Nothing to report.
DLK1, a serum marker for hepatoblastoma in young infants†
Article first published online: 16 DEC 2011
Copyright © 2011 Wiley Periodicals, Inc.
Pediatric Blood & Cancer
Volume 59, Issue 4, pages 743–745, October 2012
How to Cite
Falix, F. A., Aronson, D. C., Lamers, W. H., Hiralall, J. K. and Seppen, J. (2012), DLK1, a serum marker for hepatoblastoma in young infants. Pediatr. Blood Cancer, 59: 743–745. doi: 10.1002/pbc.24024
- Issue published online: 8 AUG 2012
- Article first published online: 16 DEC 2011
- Manuscript Accepted: 4 NOV 2011
- Manuscript Received: 3 OCT 2011
- The Netherlands Organisation for Scientific Research (NWO). Grant Number: 017.001.241 (2004)
- The Dutch Federation for Hepatology (NvH)
- serum marker
Hepatoblastoma is a malignant pediatric liver tumor. The currently used diagnostic serum marker for hepatoblastoma, α-fetoprotein (AFP), is not always reliable in infants with hepatoblastoma, due to the physiologically elevated levels of AFP in this age group. In this report, we show that Delta-like 1 homolog (DLK1), a protein highly expressed during fetal development, but almost completely absent after birth, and an established liver-stem cell marker, is a new candidate serum marker of hepatoblastoma, especially in young infants. Pediatr Blood Cancer 2012;59:743–745. © 2011 Wiley Periodicals, Inc.